ClinicalTrials.gg
CompletedNCT04744662Updated Nov 19, 2024

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

A Phase 1 interventional study of ONL1204 Ophthalmic solution and sham injection in Geographic Atrophy, sponsored by ONL Therapeutics. Completed at 8 sites in 2 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by ONL Therapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Geographic Atrophy with a site in Australia — 12 open to participants now, 15 under way, 4 of them phase 3. Geographic Atrophy · Australia.

Enrollment
33rd of 34
28 · median 280
Started
2021
with 4 others
Phase 1
Only one
of the 41
Registered
21st of 41
by date

Among the 41 studies in Geographic Atrophy with a site in Australia, this one is the 33rd largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2021, is the only one in phase 1, and was the 21st registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

12 of the 41 studies in Geographic Atrophy with a site in Australia are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Geographic Atrophy with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of intravitreal injection of ONL1204 Ophthalmic Solution in patients with geographic atrophy associated with AMD.

GA associated with AMD is one of the world's leading causes of visual disability. It is a progressive disease with no approved therapy to slow or arrest the process of continual photoreceptor and retinal epithelial (RPE) cell loss. A safe and effective therapy for GA will have vast societal benefits. ONL1204 is being developed for this purpose. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death in development for to reduce rates of vision in patients with GA associated with AMD. ONL1204 has demonstrated protection of multiple retinal cell types in several preclinical models of acute ocular injury and the protection of RPE in AMD models. ONL1204 Ophthalmic Solution is currently in a Phase 1 clinical study in patients with macula-off retinal detachment to evaluate safety and tolerability of a multi-dose of ONL1204 Ophthalmic Solution. The study is ongoing and uses the same doses and route of administration as this Phase 1b study in patients with GA.

Read the detailed description

In this study patients will be enrolled and followed for 24 weeks (natural history phase) at which point they will be randomized to 1 of 2 doses of ONL1204 Ophthalmic Solution or sham. Weeks 24 to 48 make up the Treatment Phase. Patients will be on study for a total of 48 weeks.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, ≥ 55 years old
  • Able to give and attend study visits
  • Bilateral GA secondary to AMD without choroidal neovascularization in either eye
  • ETDRS BCVA 20/400 (Snellen equivalent) or better in both eyes
  • GA ≥1 disc area (DA) (DA, 2.5 mm2)
  • If GA in study eye is multifocal, at least one focal lesion must have a DA of ≥ 1.25 mm2
  • Entire GA area must be visible within the standard FAF field of view
  • Presence of banded or diffuse hyperautofluoresence adjacent to GA lesion in study eye
  • Female subjects must be:
  • Women of non-, or
  • WOCBP with a negative pregnancy test at screening and willing to use permissible methods of for the duration of the study
  • Males with female partners of childbearing potential must agree to use permissible methods of contraception and agree to refrain from donating sperm for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • GA in either eye due to causes other than AMD
  • Participation in other ophthalmic clinical trials or use of any other drugs or devices in study eye or systemically for 6 months prior to enrollment, or anticipated participation in other ophthalmic clinical trials or use of any other investigational drugs or devices in study eye or systemically during the study period
  • Intraocular inflammation in the study eye
  • Ocular or periocular infection in the study eye
  • Media opacity that would limit baseline visual acuity or clinical visualization of the retina at baseline
  • Hyperautofluoresence adjacent to GA lesion in study eye that is focal only
  • Previous IVT treatment, history of retinal surgery, or other retinal therapeutic procedures in the study eye
  • Systemic that may interfere with retinal and cytokine expression including but not limited to (eg, oral prednisone or dexamethasone); antimetabolites (eg, methotrexate, mycophenolate mofetil, and azathioprine); T-cell inhibitors (eg, cyclosporine, tacrolimus, sirolimus); alkylating agents (eg, cyclophosphamide and chlorambucil); and biologic agents (eg, tumor necrosis factor inhibitors, interferons, lymphocyte inhibitors, and interleukin inhibitors)
  • Prior history of systemic use of pentosan polysulfate sodium (trade name Elmiron®)
  • Any ocular or systemic condition that in the opinion of the Investigator makes the subject unsuitable treatment with an investigational agent or that would compromise the safety and efficacy assessments of the trial
  • An unwillingness to elect to either a) use Age-related Eye Disease Study 2 (AREDS2) formula nutraceutical therapy for the duration of the study or b) choose not to use such therapy for the duration of the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Treatment Group A

    ONL1204 Ophthalmic solution (dose A) administered by intravitreal injection

    Drug: ONL1204 Ophthalmic solution

  • Experimental
    Treatment Group B

    ONL1204 Ophthalmic solution (dose B) administered by intravitreal injection

    Drug: ONL1204 Ophthalmic solution

  • Sham comparator
    Treatment Group C

    sham injection without penetrating the eye

    Procedure: sham injection

Interventions

  • DrugONL1204Studies of ONL1204ONL1204 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Liquid formulation administered by intravitreal (IVT) injection

  • Proceduresham injection

    sham injection is done by touching the eye surface with a syringe without a needle

06

What researchers measure

Primary outcomes

  1. Best Corrected Visual Acuity

    ETDRS chart (number of letters read)

    Time frame: up to 48 weeks

  2. Intraocular pressure

    Intraocular pressure recorded in mmHg

    Time frame: up to 48 weeks

  3. Slit lamp biomicroscopy

    Slit lamp using US FDA clinical grading scale 0-4; 0=normal, 4=very severe changes)

    Time frame: up to 48 weeks

07

Study locations

8 sites
  • Chatswood Retina
    Chatswood, New South Wales 2067, Australia
  • Retina and Eye Consultants Hurtsville
    Hurstville, New South Wales 2220, Australia
  • Retinology Institute
    Glen Iris, Victoria 3146, Australia
  • Queensland Eye Institute
    Melbourne, Victoria 4101, Australia
  • Center for Eye Rearch Australia
    Melbourne, Victoria VIC 3002, Australia
  • Sunshine Eye Surgeons
    St Albans, Victoria 3021, Australia
  • Eye Institute Limited
    Remuera, Auckland 1050, New Zealand
  • Southern Eye Specialists
    Christchurch, 8013, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Feb 2024, 31 months.

Of 13 phase 1 interventional studies under Geographic Atrophy, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2020
First posted
Feb 9, 2021
StartActual
Jul 8, 2021
Primary completionActual
Feb 29, 2024
CompletionActual
Feb 29, 2024
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04744662
Lead sponsor
ONL Therapeutics
Responsible party
Sponsor
First posted
Feb 9, 2021
Start date
Jul 8, 2021
Primary completion
Feb 29, 2024
Completion
Feb 29, 2024
Last update
Nov 19, 2024

Study contacts

Robyn Guymer, MD
principal investigator · Center for Eye Research Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONL1204

Start the discussion